Top Markets
#1 Black Phoenix Black Phoenix +355.13%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +68.86%
#4 OpenEden OpenEden +60.23%
#5 Akedo Akedo +56.95%
#6 BasedHype BasedHype +26.68%
#7 Cryptopia Cryptopia +21.54%
#8 Avantis Avantis +19.51%
#9 Humanity Humanity +19.18%
#10 Ether.fi Ether.fi +17.32%
Coin of the day
Black Phoenix Black Phoenix
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Synairgen plc Synairgen plc

Synairgen plc

SNG
Peringkat dalam Saham #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Harga Saham
$0.01292666
Terakhir disinkronkan: 2025-04-08
Kapitalisasi Pasar
$157.54K
Perubahan (1 hari)
6.84%
Perubahan (1 tahun)
0.00%
Negara
GB
Perdagangan Synairgen plc (SNG)

Kategori

Healthcare
Pendapatan untuk Synairgen plc (SNG)
Pendapatan pada Jun 2024 TTM: 0.00
Menurut laporan keuangan terbaru dari Synairgen plc, pendapatan saat ini (TTM) adalah 0.00. Pada tahun 2022, perusahaan menghasilkan pendapatan sebesar 0.00 sama dengan pendapatan pada tahun 2021 yang sebesar 0.00. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Synairgen plc dari 2004 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 $133.74 -98.03%
2017 $6.79K 0.00%
2016 0.00 -100.00%
2015 $36.84 -99.45%
2014 $6.68K 0.00%
2013 0.00 0.00%
2012 0.00 -100.00%
2011 $248.65K 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 -100.00%
2007 $156.44K 3.46%
2006 $151.21K -58.23%
2005 $361.99K 143.32%
2004 $148.77K 0.00%
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE